MANCHESTER: Yourgene Health, a leading international molecular diagnostics group, has entered into a 5-year strategic partnership with a blue chip Japanese multinational to provide Yourgene’s Flex Analysis Software bioinformatics platform for a reproductive health project.
Yourgene and the Japanese partner have entered into a technology transfer agreement which provides the Partner with access to Yourgene’s bioinformatics platform, the Flex Analysis Software, and other associated knowhow.
The Flex Software and Knowhow will enable the Partner to offer in-house bioinformatic analysis and clinical screening services to the Japanese market for a reproductive health application. Yourgene expects this partnership to deliver over USD2.5m of revenue over the contract life, as well as creating a benchmark clinical offering in this major world healthcare market.
Yourgene launched its Yourgene Flex Analysis Software, a medical grade, configurable bioinformatics software platform in October 2019, to support the Company’s ambition to develop strategic in vitro diagnostic (IVD) product development partnerships and research collaborations with key industry players.
The Flex Software allows the complex sequencing data, generated during lab workflow, to be analysed in order to produce a user friendly, easy to interpret report for clinicians, without the need for the geneticist or a bioinformation. The Partner will also take a licence for the Atlas Workflow Manager, which ensures a seamless sample tracking workflow that will link to the Flex Software.
Lyn Rees, CEO of Yourgene Health plc, commented: “We are delighted to have secured this key strategic partnership expanding and consolidating our geographical reach into Japan. This is a great endorsement of our analytical capabilities, and we are pleased to be able to customise these class-leading technology tools: Flex Software and Atlas Workflow Manager for our partner. We hope to develop future collaborations with this blue chip partner further across reproductive health and other fields.”
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and precision medicine. The Group’s products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene’s commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange‘s AIM market under the ticker “YGEN”.
Leave a Reply